Rivaroxaban Dosing for Chronic Peripheral Artery Disease with Aspirin
For chronic peripheral artery disease, rivaroxaban 2.5 mg twice daily combined with low-dose aspirin (75–100 mg once daily) is the recommended regimen to reduce major adverse cardiovascular and limb events. 1
Specific Dosing Regimen
- Rivaroxaban dose: 2.5 mg orally twice daily (approximately 12 hours apart) 2
- Aspirin dose: 75–100 mg once daily 1, 3
- Duration: Long-term, indefinite therapy without time limitation 1
- Food requirements: Can be taken with or without food 2
This combination carries a Class I (strong) recommendation from the 2024 ACC/AHA Peripheral Artery Disease Guidelines for patients with symptomatic PAD 1, 3, 4.
Evidence Supporting This Dose
- The COMPASS trial (27,395 patients) demonstrated that rivaroxaban 2.5 mg twice daily plus aspirin reduced major adverse cardiovascular events by 24% (HR 0.76,95% CI 0.66–0.86) and major adverse limb events by 46% (HR 0.54,95% CI 0.35–0.82) compared to aspirin alone 3, 4
- A meta-analysis of 11,560 PAD patients from COMPASS and VOYAGER trials confirmed consistent efficacy across the broad spectrum of PAD patients (HR 0.79,95% CI 0.65–0.95) 5
- The net clinical benefit (ischemic events prevented minus fatal/critical-organ bleeding) favored the combination therapy (HR 0.80,95% CI 0.70–0.91) 4
Important: Rivaroxaban 5 mg twice daily (without aspirin) was also studied but did not significantly reduce cardiovascular events compared to aspirin alone and is therefore not recommended 6. The 2.5 mg twice-daily dose specifically in combination with aspirin is the only evidence-based regimen 1, 3.
Post-Revascularization Timing
- After lower-extremity endovascular or surgical revascularization, initiate therapy within 10 days of the procedure once hemostasis has been established 1, 2
- Continue indefinitely for long-term secondary prevention 1
Renal Dosing Considerations
- No dose adjustment needed for any level of creatinine clearance when using the 2.5 mg twice-daily dose for PAD 2
- Patients with moderate chronic kidney disease (CrCl 30–50 mL/min) have comparable efficacy and safety 4
- Avoid use in patients with CrCl <15 mL/min or on dialysis (absolute contraindication) 1, 3
Absolute Contraindications to This Regimen
The following patients should not receive rivaroxaban 2.5 mg twice daily plus aspirin 1, 3:
- Prior hemorrhagic or lacunar stroke at any time
- Intracranial hemorrhage, intracranial tumor, or vascular malformation
- Gastrointestinal bleeding within the previous 6 months
- Acute coronary syndrome within the previous 30 days
- End-stage renal disease (eGFR <15 mL/min/1.73 m²) or dialysis
- Need for prolonged dual antiplatelet therapy (>6 months)
- Patients already on full-dose anticoagulation for other indications (creates excessive anticoagulation—Class III harmful) 1
Alternative Regimen When Rivaroxaban Is Contraindicated
- Use aspirin 75–100 mg plus clopidogrel 75 mg daily for 1–6 months, then transition to single antiplatelet therapy (Class IIa recommendation) 1, 3
- Do not substitute apixaban—it lacks evidence and FDA approval for PAD 3
Bleeding Risk Profile
- Major bleeding increases by 70% (HR 1.70,95% CI 1.40–2.05), predominantly gastrointestinal 4
- No significant increase in intracranial or fatal bleeding 3, 4
- In patients ≥75 years, the combination showed numerically greater absolute benefits without excess intracranial or fatal bleeding (2 rivaroxaban vs. 8 placebo) 7
- The number needed to treat is 26 for the primary endpoint versus number needed to harm of 123 for major bleeding 7
Common Pitfall to Avoid
Never combine rivaroxaban 2.5 mg twice daily with a P2Y12 inhibitor (e.g., clopidogrel) in addition to aspirin—this creates triple antithrombotic therapy, which markedly increases bleeding without proven efficacy benefit (Class III harmful) 1, 4. If full-dose anticoagulation is required for another indication (e.g., atrial fibrillation), use the full-dose anticoagulant plus only one antiplatelet agent, not this low-dose rivaroxaban regimen 1.